Trial Profile

A Trial Investigating the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of EV-077-3201-2TBS in Healthy Subjects and Type 2 Diabetic Subjects.

Status: Discontinued

Phase of Trial: Phase II

Latest Information Update: 07 Nov 2021

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs SER 150 (Primary) ; Aspirin
Indications Diabetic angiopathies; Diabetic complications; Thrombosis
Focus Adverse reactions; Biomarker; Pharmacogenomic; Pharmacokinetics; Therapeutic Use

Most Recent Events

03 Jun 2013 Status changed from suspended to discontinued as reported by ClinicalTrials.gov record.
05 Sep 2012 Status changed from recruiting to suspended, as reported by European Clinical Trials Database.
29 Aug 2012 Evolva Holding SA is consulting with German regulatory authority BfArM concerning liver enzyme elevations associated with EV 077, as reported in a media release from Evolva Holding SA.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com